Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the medical research company’s stock.

Several other research firms have also commented on CTSO. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Cytosorbents has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.01 on Wednesday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.59. The company has a market cap of $54.95 million, a P/E ratio of -2.79 and a beta of 0.58. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.04.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. On average, sell-side analysts forecast that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of CTSO. Atomi Financial Group Inc. purchased a new position in Cytosorbents during the third quarter worth about $51,000. Sargent Investment Group LLC lifted its holdings in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.